GALECTIN THERAPEUTICS INC
No SEC Form 4 filings for $GALT in the last 30 days.
NORCROSS, Ga., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Galectin Therapeutics, Inc. ( NASDAQ: GALT ) , the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025.
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc. ( NASDAQ: SFIX ) dipped 7.6% to $5.21 in pre-market trading following the release of fourth-quarter results.
Nashville, Tennessee, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Galata Acquisition Corp. II ( the "Company" ) announced today the closing of its initial public offering of 17,250,000 units, which includes 2,250,000 units issued pursuant to the exercise by the underwriters of their over-allotment ...
